☰

Romaine I. Fernando, Ph.D. - Publications

Affiliations: 
2004 The University of Tennessee, Knoxville, TN, United States 
Area:
Cell Biology, Molecular Biology, Oncology
Tree Info Grants Similar researchers PubMed Report error

41 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Lee SB, Pan J, Jiang Y, Palen K, Johnson B, Fernando RI, Sei S, Lubet R, You M, Wang Y. Abstract 647: Immunoprevention of triple negative breast cancer by a TOP2A multi-peptide vaccine Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-647  0.348
2017 Heery CR, Palena C, McMahon S, Donahue RN, Lepone LM, Grenga I, Dirmeier U, Cordes L, Marte JL, Dahut W, Singh H, Madan RA, Fernando RI, Hamilton DH, Schlom J, et al. Phase I Study of a Poxviral TRICOM-Based Vaccine Directed Against the Transcription Factor Brachyury. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28855356 DOI: 10.1158/1078-0432.Ccr-17-1087  0.337
2017 Tsang KY, Fantini M, Fernando RI, Palena C, David JM, Hodge JW, Gabitzsch ES, Jones FR, Schlom J. Identification and characterization of enhancer agonist human cytotoxic T-cell epitopes of the human papillomavirus type 16 (HPV16) E6/E7. Vaccine. PMID 28389098 DOI: 10.1016/J.Vaccine.2017.03.025  0.301
2016 Fernando RI, Hamilton DH, Dominguez C, David JM, McCampbell KK, Palena C. IL-8 signaling is involved in resistance of lung carcinoma cells to erlotinib. Oncotarget. PMID 27248176 DOI: 10.18632/Oncotarget.9662  0.37
2016 Jochems C, Fantini M, Fernando RI, Kwilas AR, Donahue RN, Lepone LM, Grenga I, Kim YS, Brechbiel MW, Gulley JL, Madan RA, Heery CR, Hodge JW, Newton R, Schlom J, et al. The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells. Oncotarget. PMID 27192116 DOI: 10.18632/Oncotarget.9326  0.42
2016 Jochems C, Madan RA, Fernando RI, Gulley JL, Tsang KY, Schlom J. Abstract 1406: Analysis of immune responses as a consequence of androgen deprivation therapy in patients with biochemical progression of prostate cancer Cancer Research. 76: 1406-1406. DOI: 10.1158/1538-7445.Am2016-1406  0.312
2016 Jochems C, Cereda V, Fernando RI, Richards J, Grenga I, Ferroni P, Guadagni F, Schlom J, Roselli M. Abstract 1403: Correlations between overall survival and patient regulatory T-cell levels at initiation of Folfiri therapy in colorectal cancer Cancer Research. 76: 1403-1403. DOI: 10.1158/1538-7445.Am2016-1403  0.332
2015 Hamilton DH, Fernando RI, Schlom J, Palena C. Aberrant expression of the embryonic transcription factor brachyury in human tumors detected with a novel rabbit monoclonal antibody. Oncotarget. 6: 4853-62. PMID 25605015 DOI: 10.18632/Oncotarget.3086  0.444
2015 Cekanova M, Fernando RI, Siriwardhana N, Sukhthankar M, De la Parra C, Woraratphoka J, Malone C, Ström A, Baek SJ, Wade PA, Saxton AM, Donnell RM, Pestell RG, Dharmawardhane S, Wimalasena J. BCL-2 family protein, BAD is down-regulated in breast cancer and inhibits cell invasion. Experimental Cell Research. 331: 1-10. PMID 25499972 DOI: 10.1016/J.Yexcr.2014.11.016  0.709
2015 Jochems C, Kwilas A, Kim Y, Brechbiel MW, Fantini M, Metenou S, Fernando RI, Kim PS, Gameiro S, Hodge J, Newton R, Schlom J, Tsang KY. Treatment with the IDO inhibitor INCB024360 increased lysis of human tumor cell targets by peptide-specific CTL Journal For Immunotherapy of Cancer. 3: P275. DOI: 10.1186/2051-1426-3-S2-P275  0.394
2015 Heery CR, Donahue R, Lepone L, Grenga I, Richards J, Metenou S, Fernando RI, Dirmeier U, Singh H, Madan R, Gulley JL, Schlom J. Phase I, dose-escalation, clinical trial of MVA-Brachyury-TRICOM vaccine demonstrating safety and brachyury-specific T cell responses Journal For Immunotherapy of Cancer. 3: P132. DOI: 10.1186/2051-1426-3-S2-P132  0.316
2015 Hamilton DH, Fernando RI, Tsang K, Palena C. Abstract A42: MK-1775, a WEE1 inhibitor alleviates resistance to immune attack of tumor cells undergoing an epithelial-mesenchymal transition Cancer Immunology Research. 3. DOI: 10.1158/2326-6074.Tumimm14-A42  0.519
2014 Palena C, Roselli M, Litzinger MT, Ferroni P, Costarelli L, Spila A, Cavaliere F, Huang B, Fernando RI, Hamilton DH, Jochems C, Tsang KY, Cheng Q, Lyerly HK, Schlom J, et al. Overexpression of the EMT driver brachyury in breast carcinomas: association with poor prognosis. Journal of the National Cancer Institute. 106. PMID 24815864 DOI: 10.1093/Jnci/Dju054  0.453
2014 Hamilton DH, Huang B, Fernando RI, Tsang KY, Palena C. WEE1 inhibition alleviates resistance to immune attack of tumor cells undergoing epithelial-mesenchymal transition. Cancer Research. 74: 2510-9. PMID 24626094 DOI: 10.1158/0008-5472.Can-13-1894  0.558
2014 Palena C, Fernando RI, Hamilton DH. An immunotherapeutic intervention against tumor progression: Targeting a driver of the epithelial-to-mesenchymal transition. Oncoimmunology. 3: e27220. PMID 24575384 DOI: 10.4161/Onci.27220  0.342
2013 Hamilton DH, Litzinger MT, Jales A, Huang B, Fernando RI, Hodge JW, Ardiani A, Apelian D, Schlom J, Palena C. Immunological targeting of tumor cells undergoing an epithelialmesenchymal transition via a recombinant brachyury-yeast vaccine Oncotarget. 4: 1777-1790. PMID 24125763 DOI: 10.18632/Oncotarget.1295  0.442
2013 Huang B, Cohen JR, Fernando RI, Hamilton DH, Litzinger MT, Hodge JW, Palena C. The embryonic transcription factor Brachyury blocks cell cycle progression and mediates tumor resistance to conventional antitumor therapies. Cell Death & Disease. 4: e682. PMID 23788039 DOI: 10.1038/Cddis.2013.208  0.468
2013 Larocca C, Cohen JR, Fernando RI, Huang B, Hamilton DH, Palena C. An autocrine loop between TGF-β1 and the transcription factor brachyury controls the transition of human carcinoma cells into a mesenchymal phenotype. Molecular Cancer Therapeutics. 12: 1805-15. PMID 23783250 DOI: 10.1158/1535-7163.Mct-12-1007  0.502
2013 Palena C, Fernando RI, Hamilton DH, Huang B, Schlom J. Brachyury, a driver of tumor invasiveness and resistance to multiple therapies, is a novel immunotherapy target Journal For Immunotherapy of Cancer. 1. DOI: 10.1186/2051-1426-1-S1-P230  0.514
2013 Fernando RI, Hamilton DH, Huang B, Palena C. Interleukin-8 drives epithelial-mesenchymal transition of human carcinomas Journal For Immunotherapy of Cancer. 1. DOI: 10.1186/2051-1426-1-S1-P187  0.406
2013 Hamilton DH, Huang B, Fernando RI, Tsang K, Palena C. High levels of expression of the transcription factor Brachyury induce resistance of human carcinoma cells to immune-mediated attack Journal For Immunotherapy of Cancer. 1. DOI: 10.1186/2051-1426-1-S1-P152  0.485
2013 Hamilton DH, Huang B, Fernando RI, Tsang K, Palena CM. Abstract 278: High levels of expression of the transcription factor Brachyury induce resistance of human carcinoma cells to immune-mediated attack. Cancer Research. 73: 278-278. DOI: 10.1158/1538-7445.Am2013-278  0.488
2013 Huang BK, Cohen J, Fernando RI, Hamilton DH, Litzinger MT, Hodge JW, Palena CM. Abstract 1489: The T-box transcription factor Brachyury blocks cell cycle progression and mediates tumor resistance to chemotherapy and radiation. Cancer Research. 73: 1489-1489. DOI: 10.1158/1538-7445.Am2013-1489  0.487
2012 Palena C, Hamilton DH, Fernando RI. Influence of IL-8 on the epithelial-mesenchymal transition and the tumor microenvironment Future Oncology. 8: 713-722. PMID 22764769 DOI: 10.2217/Fon.12.59  0.409
2012 Roselli M, Fernando RI, Guadagni F, Spila A, Alessandroni J, Palmirotta R, Costarelli L, Litzinger M, Hamilton D, Huang B, Tucker J, Tsang KY, Schlom J, Palena C. Brachyury, a driver of the epithelial-mesenchymal transition, is overexpressed in human lung tumors: an opportunity for novel interventions against lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 3868-79. PMID 22611028 DOI: 10.1158/1078-0432.Ccr-11-3211  0.387
2012 Hamilton DH, Litzinger MT, Fernando RI, Huang B, Palena C. Cancer vaccines targeting the epithelial-mesenchymal transition: Tissue distribution of brachyury and other drivers of the mesenchymal-like phenotype of carcinomas Seminars in Oncology. 39: 358-366. PMID 22595058 DOI: 10.1053/J.Seminoncol.2012.02.005  0.485
2011 Fernando RI, Castillo MD, Litzinger M, Hamilton DH, Palena C. IL-8 signaling plays a critical role in the epithelial-mesenchymal transition of human carcinoma cells Cancer Research. 71: 5296-5306. PMID 21653678 DOI: 10.1158/0008-5472.Can-11-0156  0.424
2011 Palena C, Fernando RI, Litzinger MT, Hamilton DH, Huang B, Schlom J. Strategies to target molecules that control the acquisition of a mesenchymal-like phenotype by carcinoma cells Experimental Biology and Medicine. 236: 537-545. PMID 21427233 DOI: 10.1258/Ebm.2011.010367  0.467
2011 Huang BK, Fernando RI, Hamilton DH, Litzinger MT, Schlom J, Palena CM. Abstract C53: Overexpression of Brachyury in human carcinoma cells drives the acquisition of resistance to anticancer therapeutics Cancer Research. 71. DOI: 10.1158/1538-7445.Fbcr11-C53  0.483
2011 Hamilton DH, Fernando R, Huang B, Tsang K, Schlom J, Palena C. Abstract A64: Brachyury-mediated epithelial-mesenchymal transition of human carcinoma cells is associated with an increased resistance to immune-mediated attack Cancer Research. 71. DOI: 10.1158/1538-7445.Fbcr11-A64  0.527
2011 Cekanova M, Fernando R, Wimalasena J. P1-02-11: The BCL2 Antagonist of Death, BAD Is Down-Regulated in Breast Cancer and Inhibits Cancer Cell Invasion. Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-P1-02-11  0.719
2010 Fernando RI, Litzinger M, Trono P, Hamilton DH, Schlom J, Palena C. The T-box transcription factor Brachyury promotes epithelial-mesenchymal transition in human tumor cells Journal of Clinical Investigation. 120: 533-544. PMID 20071775 DOI: 10.1172/Jci38379  0.496
2010 Fernando R, Cekanova M, Worraratphoka J, Sukhthankar M, Siriwardhana N, Moustaid-Moussa N, Baek S, Donnel R, Strom A, Wang Q, Zou M, Wimalasena J. Abstract 1046: BAD is a multifunctional protein in breast cancer cells Cancer Research. 70: 1046-1046. DOI: 10.1158/1538-7445.Am10-1046  0.708
2007 Fernando R, Foster JS, Bible A, Ström A, Pestell RG, Rao M, Saxton A, Baek SJ, Yamaguchi K, Donnell R, Cekanova M, Wimalasena J. Breast cancer cell proliferation is inhibited by BAD: regulation of cyclin D1. The Journal of Biological Chemistry. 282: 28864-73. PMID 17670745 DOI: 10.1074/Jbc.M700785200  0.704
2007 Litzinger MT, Fernando R, Curiel TJ, Grosenbach DW, Schlom J, Palena C. IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity. Blood. 110: 3192-201. PMID 17616639 DOI: 10.1182/Blood-2007-06-094615  0.328
2007 Palena C, Polev DE, Tsang KY, Fernando RI, Litzinger M, Krukovskaya LL, Baranova AV, Kozlov AP, Schlom J. The human T-box mesodermal transcription factor Brachyury is a candidate target for T-cell-mediated cancer immunotherapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 2471-8. PMID 17438107 DOI: 10.1158/1078-0432.Ccr-06-2353  0.435
2007 Henley D, Isbill M, Fernando R, Foster JS, Wimalasena J. Paclitaxel induced apoptosis in breast cancer cells requires cell cycle transit but not Cdc2 activity. Cancer Chemotherapy and Pharmacology. 59: 235-49. PMID 16972069 DOI: 10.1007/S00280-006-0262-1  0.677
2004 Fernando RI, Wimalasena J. Estradiol abrogates apoptosis in breast cancer cells through inactivation of BAD: Ras-dependent nongenomic pathways requiring signaling through ERK and Akt. Molecular Biology of the Cell. 15: 3266-84. PMID 15121878 DOI: 10.1091/Mbc.E03-11-0823  0.687
2003 Foster JS, Fernando RI, Ishida N, Nakayama KI, Wimalasena J. Estrogens down-regulate p27Kip1 in breast cancer cells through Skp2 and through nuclear export mediated by the ERK pathway. The Journal of Biological Chemistry. 278: 41355-66. PMID 12904306 DOI: 10.1074/Jbc.M302830200  0.708
2003 Bukovsky A, Indrapichate K, Fujiwara H, Cekanova M, Ayala ME, Dominguez R, Caudle MR, Wimalsena J, Elder RF, Copas P, Foster JS, Fernando RI, Henley DC, Upadhyaya NB. Multiple luteinizing hormone receptor (LHR) protein variants, interspecies reactivity of anti-LHR mAb clone 3B5, subcellular localization of LHR in human placenta, pelvic floor and brain, and possible role for LHR in the development of abnormal pregnancy, pelvic floor disorders and Alzheimer's disease. Reproductive Biology and Endocrinology : Rb&E. 1: 46. PMID 12816543 DOI: 10.1186/1477-7827-1-46  0.326
2003 Bukovsky A, Caudle MR, Cekanova M, Fernando RI, Wimalasena J, Foster JS, Henley DC, Elder RF. Placental expression of estrogen receptor beta and its hormone binding variant--comparison with estrogen receptor alpha and a role for estrogen receptors in asymmetric division and differentiation of estrogen-dependent cells. Reproductive Biology and Endocrinology : Rb&E. 1: 36. PMID 12740031 DOI: 10.1186/1477-7827-1-36  0.614
Show low-probability matches.